Search - tctmd.com

Displaying 341 - 360 of 422

Sort: Relevancy | Date

News Daily News

Un Nuevo Anti Inflamatorio podría Reducir la Estenosis tras la Implantación de SMD en Pacientes de Alto Riesgo

L.A. McKeown

January 13, 2013

News Daily News

CABG More Cost-Effective in Patients with Diabetes, Multivessel Disease Over Long Term

Yael L. Maxwell

January 09, 2013

News Daily News

TCTMD’s Top 10 Most Popular News Stories for 2012

Jason Kahn

January 02, 2013

News Daily News

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Caitlin E. Cox

December 26, 2012

News Daily News

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Caitlin E. Cox

December 26, 2012

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Jason Kahn

December 05, 2012

News Daily News

BELLO: Drug-Coated Balloons Take on De Novo Lesions vs. DES

Caitlin E. Cox

November 15, 2012

News Conference News TCT 2012

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

November 02, 2012

News Daily News

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Jason Kahn

October 05, 2012

News Daily News

Korean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting Stents

September 19, 2012

News Daily News

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

Yael L. Maxwell

September 07, 2012

News Conference News ESC 2012

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Caitlin E. Cox

August 29, 2012

News Conference News ESC 2012

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

August 27, 2012

News Daily News

SORT OUT III: Higher Risk of Very Late Stent Thrombosis with Cypher vs. Endeavor

L.A. McKeown

August 23, 2012

News Industry News

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 20, 2012

News Daily News

Study Suggests Shortening Delay to Noncardiac Surgery After PCI

Yael L. Maxwell

August 17, 2012

News Industry News

Cardionovum® expects to launch next-generation product: drug-eluting coronary stent system, PROLIMUS Biograde

August 08, 2012

News Daily News

Halving DES Use in Low-Risk Patients Could Save $200 Million Annually

Yael L. Maxwell

July 11, 2012

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Conference News EuroPCR 2012

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Caitlin E. Cox

May 18, 2012

Advertisement

Un Nuevo Anti Inflamatorio podría Reducir la Estenosis tras la Implantación de SMD en Pacientes de Alto Riesgo

CABG More Cost-Effective in Patients with Diabetes, Multivessel Disease Over Long Term

TCTMD’s Top 10 Most Popular News Stories for 2012

Real-World Equivalence Seen for Zotarolimus- and Everolimus-Eluting Stents

Equivalencia en el Mundo Real Confirmada de los Stents liberadores de Zotarolimus y Everolimus

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

BELLO: Drug-Coated Balloons Take on De Novo Lesions vs. DES

COMPARE II: Biolimus-Eluting Stent Rivals Everolimus-Eluting Stent in All-Comers Trial

Drug-eluting Balloons Show Positive Results in Treating In-stent Restenosis

Korean Registry Confirms Edge of Everolimus- Over Zotarolimus-Eluting Stents

SORT OUT IV: Xience Holds Edge Over Cypher for Preventing Stent Thrombosis

OCTOPUS Looks at Vessel Healing After DES vs. BMS Plus Paclitaxel Balloon

Stent Thrombosis Surprise: Rates Low, Similar for Endeavor and Cypher at 3 Years

SORT OUT III: Higher Risk of Very Late Stent Thrombosis with Cypher vs. Endeavor

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

Study Suggests Shortening Delay to Noncardiac Surgery After PCI

Cardionovum® expects to launch next-generation product: drug-eluting coronary stent system, PROLIMUS Biograde

Halving DES Use in Low-Risk Patients Could Save $200 Million Annually

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content